Potential eligibility for Aducanumab therapy in an Irish specialist cognitive service—Utilising cerebrospinal fluid biomarkers and appropriate use criteria-Reference-Cited by-同舟云学术

Potential eligibility for Aducanumab therapy in an Irish specialist cognitive service—Utilising cerebrospinal fluid biomarkers and appropriate use criteria

Published:2022-07-21 Issue:8 Volume:37 Page:
ISSN:0885-6230
Container-title:International Journal of Geriatric Psychiatry
language:en
Short-container-title:Int J Geriat Psychiatry

Author:

Togher Zara¹^ORCID,Dolphin Helena²,Russell Caoimh¹,Ryan Marie¹,Kennelly Séan P.²,O'Dowd Séan¹²

Affiliation:

1. Department of Neurology Tallaght University Hospital Dublin Ireland

2. Institute of Memory and Cognition Tallaght University Hospital Dublin Ireland

Publisher

Wiley

Subject

Psychiatry and Mental health,Geriatrics and Gerontology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/gps.5789

Reference15 articles.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer’s disease;Journal of Neurology, Neurosurgery & Psychiatry;2024-06-11

2. Navigating the future of Alzheimer’s care in Ireland - a service model for disease-modifying therapies in small and medium-sized healthcare systems;BMC Health Services Research;2024-06-05

3. Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with MCI or early AD in the general population;2024-02-29

4. Real-word application of the AT(N) classification and disease-modifying treatment eligibility in a hospital-based cohort;Journal of Neurology;2024-02-21

5. New horizons in the diagnosis and management of Alzheimer’s Disease in older adults;Age and Ageing;2024-02-01